Retirement Systems of Alabama Takes $12.10 Million Position in Elanco Animal Health Incorporated $ELAN

Retirement Systems of Alabama purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 600,677 shares of the company’s stock, valued at approximately $12,098,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Sector Gamma AS boosted its holdings in shares of Elanco Animal Health by 5.2% during the 3rd quarter. Sector Gamma AS now owns 307,271 shares of the company’s stock valued at $6,188,000 after buying an additional 15,198 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp purchased a new position in Elanco Animal Health during the 3rd quarter valued at about $1,444,000. Arkadios Wealth Advisors lifted its position in Elanco Animal Health by 7.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 52,216 shares of the company’s stock valued at $1,052,000 after acquiring an additional 3,434 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in Elanco Animal Health by 41.3% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 16,277 shares of the company’s stock worth $333,000 after acquiring an additional 4,761 shares in the last quarter. Finally, Amalgamated Bank grew its holdings in Elanco Animal Health by 793.7% in the third quarter. Amalgamated Bank now owns 226,580 shares of the company’s stock worth $4,563,000 after purchasing an additional 201,226 shares during the period. Institutional investors own 97.48% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ELAN shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 29th. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Barclays began coverage on Elanco Animal Health in a research note on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price objective for the company. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. Finally, Zacks Research downgraded Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average target price of $25.11.

Insiders Place Their Bets

In related news, CEO Jeffrey N. Simmons acquired 22,000 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was purchased at an average cost of $21.75 per share, with a total value of $478,500.00. Following the completion of the acquisition, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at approximately $3,632,250. This trade represents a 15.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Rajeev A. Modi acquired 4,500 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, December 11th. The shares were purchased at an average price of $21.33 per share, with a total value of $95,985.00. Following the transaction, the insider owned 123,082 shares of the company’s stock, valued at $2,625,339.06. The trade was a 3.79% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 43,450 shares of company stock worth $937,883 in the last 90 days. Corporate insiders own 0.89% of the company’s stock.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $24.14 on Thursday. The firm has a market cap of $11.99 billion, a P/E ratio of 402.37, a PEG ratio of 3.42 and a beta of 1.87. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $25.29. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. The company has a 50 day moving average of $22.93 and a 200 day moving average of $20.22.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter last year, the company earned $0.13 EPS. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.